Clinical Trial Update: Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the efficacy, safety and tolerability of canakinumab (ACZ885) in pediatric and young adult patients with sickle cell anemia; r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• Canakinumab (canakinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Sickle Cell Anemia | Phase 2 | Status: COMPLETED | Results posted: 2020-12-17